Company Encyclopedia
View More
name
Greenwich Lifesciences
GLSI.US
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc.
1.946 T
GLSI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Greenwich Lifesciences Provides Global Update On Flamingo-01

    Dec 3 (Reuters) - Greenwich Lifesciences Inc:* GREENWICH LIFESCIENCES PROVIDES GLOBAL UPDATE ON FLAMINGO-01, SCREENING OVER 1,000 PATIENTS TO DATE Source text: Further company coverage:

    Reuters·
    US
    GLSI
    +4.64%
    Reuters·
    US
    GLSI
    +4.64%

    Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $38,502.00 in Stock

    Greenwich LifeSciences CEO Snehal Patel purchased 4,600 shares of the company's stock at $8.37 per share, totaling $38,502. This transaction increased his ownership by 0.08%, now holding 5,588,102 shares valued at $46,772,413.74. The purchase was disclosed in an SEC filing. Patel has made other recent purchases, including 10,600 shares on November 7th and 2,300 shares on October 31st. The stock has a 52-week range of $7.78 to $15.47 and a market cap of $120.61 million.

    Market Beat·
    US
    GLSI
    +4.64%
    Market Beat·
    US
    GLSI
    +4.64%

    CEO Patel Buys 4,600 ($38.5K) Of Greenwich Lifesciences Inc [GLSI]

    Patel Snehal Chief Executive Officer of Greenwich Lifesciences Inc [GLSI] filed a Form 4 on November 28, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/25/25TransactionPurchaseShares4,600Price$8.37Value$38,502Ending Holdings: 5,588,102 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    GLSI
    +4.64%
    Reuters·
    US
    GLSI
    +4.64%

    Greenwich LifeSciences CEO and CFO Snehal Patel Acquires Common Shares

    Snehal Patel, CEO and CFO of Greenwich LifeSciences Inc., has acquired common shares of the company, as reported in a regulatory filing. This information was published via EDGAR by the U.S. Securities and Exchange Commission.

    Reuters·
    US
    GLSI
    +4.64%
    Reuters·
    US
    GLSI
    +4.64%

    Greenwich Lifesciences | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    GLSI
    +4.64%
    LB filings·
    US
    GLSI
    +4.64%
    © 2025 Longbridge｜Disclaimer